[go: up one dir, main page]

MX2011011733A - Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos. - Google Patents

Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.

Info

Publication number
MX2011011733A
MX2011011733A MX2011011733A MX2011011733A MX2011011733A MX 2011011733 A MX2011011733 A MX 2011011733A MX 2011011733 A MX2011011733 A MX 2011011733A MX 2011011733 A MX2011011733 A MX 2011011733A MX 2011011733 A MX2011011733 A MX 2011011733A
Authority
MX
Mexico
Prior art keywords
compounds
dehydrogenasee
virostatic
dihydroorotate
inhibitors
Prior art date
Application number
MX2011011733A
Other languages
English (en)
Inventor
Johann Leban
Daniel Vitt
Manfred Groeppel
Roland Baumgartner
Original Assignee
4Sc Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43030861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011011733(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 4Sc Ag filed Critical 4Sc Ag
Publication of MX2011011733A publication Critical patent/MX2011011733A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos de la fórmula general (I) y sus sales y derivados funcionales desde el punto de vista fisiológico (ver fórmula (I)) que pueden usarse como medicamentos.
MX2011011733A 2009-05-04 2010-05-04 Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos. MX2011011733A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17525509P 2009-05-04 2009-05-04
EP09159358 2009-05-04
PCT/EP2010/056042 WO2010128050A2 (en) 2009-05-04 2010-05-04 Anti-inflammatory agents as virostatic compounds

Publications (1)

Publication Number Publication Date
MX2011011733A true MX2011011733A (es) 2012-02-01

Family

ID=43030861

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011733A MX2011011733A (es) 2009-05-04 2010-05-04 Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.

Country Status (16)

Country Link
US (1) US8354433B2 (es)
EP (1) EP2427186B1 (es)
CN (1) CN102458389A (es)
AR (1) AR076837A1 (es)
AU (1) AU2010244462B2 (es)
CA (1) CA2761130C (es)
CO (1) CO6450622A2 (es)
ES (1) ES2909738T3 (es)
MX (1) MX2011011733A (es)
NZ (1) NZ596014A (es)
PE (1) PE20120898A1 (es)
SG (1) SG175854A1 (es)
TW (1) TWI530286B (es)
UY (1) UY32605A (es)
WO (1) WO2010128050A2 (es)
ZA (1) ZA201108131B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108760C2 (uk) * 2010-07-01 2015-06-10 Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби
WO2013009678A2 (en) * 2011-07-08 2013-01-17 Indiana University Research And Technology Corporation Compositions and methods for the treatment of norovirus infection
CA2944570A1 (en) * 2014-04-11 2015-10-15 Panoptes Pharma Gmbh Anti-inflammatory agents as virostatic compounds
ES2960598T3 (es) 2014-05-08 2024-03-05 Kiora Pharmaceuticals Gmbh Compuestos para el tratamiento de enfermedades y trastornos oftálmicos
EP3589286B1 (en) 2017-03-02 2022-08-03 ASLAN Pharmaceuticals Pte Ltd Dhodh inhibitor for treating haematological cancer
EP3761960B1 (en) 2018-03-09 2023-11-22 Kiora Pharmaceuticals GmbH Ophthalmic formulation
US20220227720A1 (en) * 2019-05-07 2022-07-21 Universitat Hamburg Dhodh inhibitors and their use as antiviral agents
US11376232B2 (en) * 2020-04-21 2022-07-05 Immunic Ag Vidofludimus for use in the treatment or prevention of viral diseases
WO2022045984A1 (en) * 2020-08-31 2022-03-03 Aslan Pharmaceuticals Pte Ltd Treatment and/or prevention of a viral infection
WO2022196236A1 (ja) * 2021-03-18 2022-09-22 国立大学法人 鹿児島大学 抗薬剤耐性インフルエンザウイルス剤及び抗薬剤耐性インフルエンザウイルス剤の製造のための化合物の使用
MX2023011864A (es) 2021-04-09 2023-11-28 Immunic Ag Inhibidores de dihidroorotato deshidrogenasa deuterados.
EP4119138A1 (en) * 2021-07-12 2023-01-18 Universität Hamburg Dhodh inhibitors and their use as antiviral agents
UY40087A (es) 2021-12-23 2023-06-30 Immunic Ag Inhibidores de DHODH que contienen un bioisóstero de ácido carboxílico.
US20230278979A1 (en) * 2022-03-01 2023-09-07 Kiora Pharmaceuticals Gmbh Salts of a dihydroorotate dehydrogenase (dhod) inhibitor
AU2023230874A1 (en) * 2022-03-09 2024-09-19 Kiora Pharmaceuticals Gmbh Polymorphs of a dihydroorotate dehydrogenase (dhod) inhibitor
EP4531834A1 (en) 2022-06-01 2025-04-09 Immunic AG Treatment of ulcerative colitis comprising vidofludimus or a pharmaceutically acceptable salt thereof
CN121399105A (zh) 2023-06-28 2026-01-23 埃慕尼克股份公司 杂芳族dhodh抑制剂
CN116803387A (zh) * 2023-07-25 2023-09-26 徐州医科大学 Vidofludimus在制备戊型肝炎药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19860802A1 (de) * 1998-12-30 2000-10-26 Virgene Pharmaceuticals Ag Herstellung eines Mittels gegen Hepatitis B-, HI-, Paramyxo und Orthomyxo-Viren
WO2001024785A2 (en) * 1999-10-01 2001-04-12 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
MXPA04000224A (es) * 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
AU2003293914B2 (en) * 2002-12-23 2010-09-23 Panoptes Pharma Ges.M.B.H. Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7071355B2 (en) * 2002-12-23 2006-07-04 4 Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056747A1 (en) * 2002-12-23 2004-07-08 4Sc Ag Dhodh-inhibitors and method for their identification
WO2005018330A1 (en) * 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico

Also Published As

Publication number Publication date
TW201043228A (en) 2010-12-16
NZ596014A (en) 2013-06-28
UY32605A (es) 2010-12-31
CO6450622A2 (es) 2012-05-31
EP2427186A2 (en) 2012-03-14
TWI530286B (zh) 2016-04-21
CN102458389A (zh) 2012-05-16
CA2761130C (en) 2017-03-28
WO2010128050A3 (en) 2011-05-05
AU2010244462A1 (en) 2011-11-17
ZA201108131B (en) 2012-07-25
PE20120898A1 (es) 2012-08-24
US20100280081A1 (en) 2010-11-04
US8354433B2 (en) 2013-01-15
WO2010128050A2 (en) 2010-11-11
AU2010244462B2 (en) 2015-07-02
CA2761130A1 (en) 2010-11-11
AR076837A1 (es) 2011-07-13
ES2909738T3 (es) 2022-05-10
EP2427186B1 (en) 2022-01-12
SG175854A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
MX2011011733A (es) Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
GEAP202213376A (en) Inhibitors of influenza viruses replication
MX2011011094A (es) Derivados de prolina como inhibidores de catepsina.
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
MY183312A (en) Pharmaceutical formulation
PH12012502216A1 (en) Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienyl-methylbenzene derivatives as inhibitors of sglt
MX2011013884A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas.
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
TN2011000291A1 (en) Purine compounds
IN2012DN03182A (es)
MX2011012739A (es) Derivados fluorados de aminotriazol.
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
IN2012DN02139A (es)
IN2012DN01292A (es)
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
GEP20156244B (en) New tertiary 8-hydroxyquinoline-7- carboxamide derivatives and usage thereof
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
TN2012000105A1 (en) Spirolactam derivatives and uses of same
MX346090B (es) Derivados de pirrolidina usados como inhibidores de catepsina.
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
MX2012007253A (es) Derivados triciclicos y sus usos y composiciones farmaceuticas.
MX2012007426A (es) Derivados de amino-heteroarilo como bloqueadores de los canales activados por la hiperpolarizacion, controlados por nucleotidos ciclicos.
MX2012004087A (es) Sulfonamidas para la prevencion de diabetes.

Legal Events

Date Code Title Description
FG Grant or registration